Michael Deininger
Mike and Cathy White Endowed Chair, EVP, Chief Scientific Officer · Medical College of Wisconsin Affiliated Hospitals, Inc
Credentials: · · · · · · ·
History
Institute of Medical Oncology and Haematology
Internal Medicine
University of Würzburg Medical School, Germany
Research
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
New England Journal of Medicine · 2006 · 2,720 citations
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
New England Journal of Medicine · 2012 · 1,753 citations
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Review · Blood · 2013 · 1,532 citations
108 papers
42 papers
33 papers
- MM
32 papers
- MT
30 papers
29 papers
- ML
28 papers · 3 as a fellow
26 papers
Grants
- 2023–2028
The Function of MS4A3 in Normal and Malignant Hematopoiesis
National Cancer Institute · R01
Contact PI · $2M · University of Michigan at Ann Arbor
- 2021–2026
Strategies to Target BCR-ABL1 Compound Mutants in CML and Ph+ ALL
National Cancer Institute · R01
Contact PI · $1.8M · Versiti Blood Health, Inc.
- 2021–2025
A Bioluminescent Assay for Direct Measurement of Sirtuin Activity in Cancer Cells
National Cancer Institute · R21
Contact PI · $605.6K · Versiti Blood Health, Inc.
- 2020–2025
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia
National Cancer Institute · R01
Contact PI · $2.9M · Versiti Blood Health, Inc.
Clinical trials
- 2011–2014
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Principal investigator · Completed · Phase 2
University of Utah
- 2005–2009
Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Study chair · Terminated · Phase 2
OHSU Knight Cancer Institute